LIVIMMUNE
LIVE

Serial Number

98115520

Owner

CytoDyn Inc.

Attorney

Jared M. Barrett

Filing Date

Aug 3, 2023

Add to watchlist:

No watchlists yet
View on USPTO

LIVIMMUNE Trademark

Serial Number: 98115520

LIVIMMUNE is a trademark filed by CytoDyn Inc. on August 3, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

CytoDyn Inc. (14 trademarks)

1111 Main Street, Suite 660
Vancouver, WA 98660

Entity Type: 03

Trademark Details

Filing Date

August 3, 2023

Registration Date

Not Registered

Published for Opposition

June 11, 2024

Goods & Services

Therapeutic preparations, namely, therapeutic preparations for the treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19, and therapeutic preparations for the prevention of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; therapeutic preparations, namely, antibodies for use in targeting the CCR5 cell receptor

Providing health and medical information, and providing health and medical information in the nature of providing a website featuring information in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; providing a website featuring medical information; providing a website featuring medical information in the field of antibodies for use in targeting the CCR5 cell receptor; medical analysis services, namely, medical analysis services in the field of antibodies for use in targeting the CCR5 cell receptor, and medical analysis services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19

Scientific research consulting services, namely, scientific research consulting services in the field of immunology, and scientific research consulting services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services, and medical research services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services in the field of antibodies for use in targeting the CCR5 cell receptor

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 16, 2026 EXRA
SOU EXTENSION 4 GRANTED
Jul 16, 2026 EX4G
SOU EXTENSION 4 FILED
Jul 15, 2026 EXT4
SOU TEAS EXTENSION RECEIVED
Jul 15, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 14, 2026 EXRA
SOU EXTENSION 3 GRANTED
Feb 5, 2026 EX3G
SOU EXTENSION 3 FILED
Feb 5, 2026 EXT3
SOU TEAS EXTENSION RECEIVED
Feb 5, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 7, 2025 EXRA
SOU EXTENSION 2 GRANTED
Aug 6, 2025 EX2G
SOU EXTENSION 2 FILED
Aug 6, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Aug 6, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 6, 2025 EXRA
SOU EXTENSION 1 GRANTED
Feb 6, 2025 EX1G
SOU EXTENSION 1 FILED
Feb 5, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Feb 5, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 6, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 11, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jun 11, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 22, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 6, 2024 CNSA
ASSIGNED TO EXAMINER
Apr 4, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 1, 2023 NWOS
NEW APPLICATION ENTERED
Aug 7, 2023 NWAP